 |
|
Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy
Anthony V. D’Amico, MD, PhD;
Andrew A. Renshaw, MD;
Brenda Sussman, RN, OCN;
Ming-Hui Chen, PhD
JAMA. 2005;294:440-447.
Context Men with localized prostate cancer and a preoperative prostate-specific antigen (PSA) velocity greater than 2.0 ng/mL per year experience a 10-fold increase in prostate cancer–specific mortality despite surgery.
Objective To assess whether a greater than 2.0-ng/mL increase in PSA level during the year prior to diagnosis was significantly associated with prostate cancer–specific mortality following radiation therapy (RT).
Design, Setting, and Patients Between January 1, 1989, and December 1, 2002, 358 men treated with RT for localized prostate cancer formed the study cohort (median age at treatment, 71.2 [range, 43.2-83.5] years). A Cox regression multivariable analysis was used to evaluate whether a PSA velocity greater than 2.0 ng/mL per year was significantly associated with prostate cancer–specific mortality and all-cause mortality after controlling for prognostic factors available at diagnosis.
Main Outcome Measure Time to prostate cancer–specific mortality for the 125 men with low-risk prostate cancer (clinical tumor category T1c or T2a and PSA level <10.0 ng/mL and Gleason score  6) and the 233 men with higher-risk disease, stratified by the PSA velocity.
Results A PSA velocity greater than 2.0 ng/mL per year was significantly associated with a shorter time to prostate cancer–specific mortality (adjusted hazard ratio [HR], 12.0; 95% confidence interval [CI], 3.0-54.0; P = .001) and all-cause mortality (adjusted HR, 2.1; 95% CI, 1.3-3.6; P = .005) when compared with men whose PSA velocity was 2.0 ng/mL per year or less. Men presenting with low-risk disease and a PSA velocity greater than 2.0 ng/mL per year had a 7-year estimate of prostate cancer–specific mortality of 19% (95% CI, 2%-39%) compared with 0% for men whose PSA velocity was 2.0 ng/mL per year or less. The corresponding values for men with higher-risk disease were 24% (95% CI, 12%-37%) and 4% (95% CI, 0%-11%), respectively.
Conclusions A greater than 2.0-ng/mL increase in PSA level during the year prior to diagnosis is associated with a significantly higher risk of death due to prostate cancer following RT despite having low-risk disease. Such men who are planning to undergo RT and are in good health could be considered for RT combined with androgen suppression therapy because this approach improves survival in men with higher-risk disease.
Author Affiliations: Departments of Radiation Oncology (Dr D’Amico and Ms Sussman) and Pathology (Dr Renshaw), Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, Mass; and Department of Statistics, University of Connecticut, Storrs (Dr Chen).
RELATED ARTICLES
Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
Stephen J. Freedland, Elizabeth B. Humphreys, Leslie A. Mangold, Mario Eisenberger, Frederick J. Dorey, Patrick C. Walsh, and Alan W. Partin
JAMA. 2005;294(4):433-439.
ABSTRACT
| FULL TEXT
PSA Kinetics and Risk of Death From Prostate Cancer: In Search of the Holy Grail of Surrogate End Points
Mitchell S. Anscher
JAMA. 2005;294(4):493-494.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort
Mucci et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1682-1688.
ABSTRACT
| FULL TEXT
Case 15-2008 -- A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer
Barry et al.
NEJM 2008;358:2161-2168.
FULL TEXT
What to Do with an Abnormal PSA Test
Loeb and Catalona
The Oncologist 2008;13:299-305.
ABSTRACT
| FULL TEXT
Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population
Ulmert et al.
JCO 2008;26:835-841.
ABSTRACT
| FULL TEXT
Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort
Mucci et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:249-251.
ABSTRACT
| FULL TEXT
Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence
Etzioni et al.
JNCI J Natl Cancer Inst 2007;99:1510-1515.
ABSTRACT
| FULL TEXT
Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer
Fall et al.
JNCI J Natl Cancer Inst 2007;99:526-532.
ABSTRACT
| FULL TEXT
Incremental Value of Multiplanar Cross-Referencing for Prostate Cancer Staging with Endorectal MRI
Wang et al.
Am. J. Roentgenol. 2007;188:99-104.
ABSTRACT
| FULL TEXT
External-beam radiotherapy for localized prostate cancer.
Pisansky
NEJM 2006;355:1583-1591.
FULL TEXT
Six-Month Androgen Suppression Plus Radiation Therapy Compared With Radiation Therapy Alone for Men With Prostate Cancer and a Rapidly Increasing Pretreatment Prostate-Specific Antigen Level
D'Amico et al.
JCO 2006;24:4190-4195.
ABSTRACT
| FULL TEXT
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Miller et al.
JNCI J Natl Cancer Inst 2006;98:1134-1141.
ABSTRACT
| FULL TEXT
Viewpoint: expanding prostate cancer screening.
Catalona et al.
ANN INTERN MED 2006;144:441-443.
ABSTRACT
| FULL TEXT
Radiation Dose Escalation as Treatment for Clinically Localized Prostate Cancer: Is More Really Better?
DeWeese and Song
JAMA 2005;294:1274-1276.
FULL TEXT
PSA Velocity and Prostate Cancer Mortality
JWatch General 2005;2005:1-1.
FULL TEXT
PSA Kinetics and Risk of Death From Prostate Cancer: In Search of the Holy Grail of Surrogate End Points
Anscher
JAMA 2005;294:493-494.
FULL TEXT
|
